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To compare the morbidity in patients with newly diagnosed clinically localized
prostate cancer managed conservatively with the morbidity in a randomly
selected age-matched background population with no history of prostate cancer.
Patients younger than 75 y at diagnosis with newly diagnosed clinically
localized prostate cancer reported to the Danish Cancer Registry in the period
1977–1992. Morbidity in patients and age-matched controls was extracted from
The Danish Hospital Discharge Registry. Admissions were stratified by discharge
diagnosis.
Overall 4744 patients were hospitalized for 251,695 days within the first 10 y
following diagnosis compared with 74,563 days in 4774 age-matched controls.
The patients were admitted 6.7 (6.4–7.1) times more often than controls in the
year following diagnosis, and 2.7 (2.6–2.8) times more often in the following 9 y.
Excess morbidity declined over time. When prostate cancer-related admissions
were excluded, the relative risk of admission was reduced to 1.35 (1.3–1.4) and
0.86 (0.83–0.89), respectively. The estimated costs associated with deferred therapy
in patients with clinically localized prostate cancer exceeded the estimated cost in
age-matched controls by approximately US$88 million, equivalent to an average
extra cost per patient of approximately US$18,500.
Patients with clinically localized prostate cancer managed conservatively had a
significantly higher morbidity than age-matched controls due to admissions
associated with prostate cancer. In future comparisons of treatment strategies,
morbidity following treatment and impact on quality of life have to be included
when evaluating the outcome.
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Introduction
No clear consensus exists as to the optimal management
of clinically localized prostate cancer (PC).1,2 In younger
patients managed expectantly, localized PC will progress,
leading to morbidity associated with advanced PC. Pre-
vious studies have demonstrated that patients with PC
managed with deferred therapy need repeated hospital
admissions and palliative treatments. However, these
studies have included patients in different clinical
stages, and morbidity has not been compared to the
background population.3–6
*Correspondence: K Brasso, Department of Urology, Rigshospitalet,
University of Copenhagen, Blegdamsvej 9, DK-2100 Ø, Denmark.
Received 1 September 1999; accepted 1 November 1999
Prostate Cancer and Prostatic Diseases (1999) 2, 253–256
ß 2000 Macmillan Publishers Ltd All rights reserved 1365–7852/99 $15.00
www.nature.com/pcan
The Danish attitude towards PC has been conservative.
Nationwide registries on incident cancer cases and hos-
pitalizations, added to the possibility of accurate linkage
across registries, offer unique opportunities for studying
the impact of PC managed with deferred endocrine
therapy. In a historical prospective population-based
case–control study we have compared the morbidity in
patients with newly diagnosed clinically localized PC to
the morbidity in an age-matched background population.
Materials and methods
The study is based on a computerized linkage between
two population-based registries; the Danish Cancer Reg-
istry (DCR) and the Danish Hospital Discharge Registry
(DHDR).
The Danish Cancer Registry has recorded incident
cases of cancer on a nationwide basis in Denmark since
1943. Reporting was voluntary until 1987, when reporting
became mandatory. The registry is regarded as almost
complete.7 Records on PC include information on the
clinical age at diagnosis recorded as localized, regional,
metastatic or unknown.
The DHDR, established in 1977, contains information
on hospitalizations in Denmark with the general excep-
tion of psychiatric wards. Records include information on
the duration of hospitalization and discharge diagnoses
based on the International Classification of Diseases
(ICD). In both registries the identification of individual
patients is based on a unique Central Personal Registra-
tion number.
All patients with newly diagnosed PC reported to the
DCR in the period from 1977 to 1992 were identified.
Patients age 74 or younger with clinically localized PC at
diagnosis were extracted. Patients in whom diagnosis
was based on autopsy findings or death certificate infor-
mation only were excluded.
Each case was matched with one control. Suitable
controls should meet the following criteria:
1. Same year and month of birth as the matching case.
2. Alive with residence in Denmark at the time of diag-
nosis of the matching case.
3. No record of PC before 1992 in DCR.
A random match procedure based on the Central
Personal Registration number was performed. Informa-
tion on the number and duration of hospitalizations was
extracted from DHDR in the period 1 January 1977 to 31
December 1994. Admissions were considered related to
PC if PC (ICD8 code 185 or ICD10 code DC61.9) was
recorded as discharge diagnosis. The linkage between
registers and data analysis was based on specially
designed computer software (Data Medica, Copenhagen).
Follow-up on cases and controls were terminated 31
December 1994, or earlier if one of the pair died before.
The morbidity of patients compared to controls is
described as the ratio between admission (adm.) rates,
relative morbidity, defined as ((no. adm.=patient=y)=(no.
adm.=control=y)), and as the difference between time
spent in hospital, excess morbidity, defined as (no. days=
patient=y)7 (no. days=control=y). The admission-rate
and the need for hospitalization were analyzed for the
year of diagnosis, ie 365 days following the date of
diagnosis and the following 9 y, respectively. The cost
associated with hospital care was calculated based on
the average price for hospitalization in Denmark.8
Trends were analyzed using a w2-test for trend. Differ-
ences between admission rates were tested using a rate-
ratio and score test9 and reported as relative risks (RR)
with 95% confidence limits.
Results
A total of 4884 patients with clinically localized PC age 74
or younger at diagnosis were identified; 94 patients were
excluded since diagnosis was based on either autopsy
findings or death certificate only. In 4713 (98.4%) of the
patients diagnosis was based on histological examination,
and in a further 23 (0.5%) on cytological examination. In
54 patients (1.1%) no information on verification was
available. Median age at diagnosis was 69 y, range 37–
74. Following the matching procedure, an additional 16
patients were excluded as no matching controls were
found for technical reasons. The study population thus
consists of 4774 matched pairs.
In the year of diagnosis patients on average had 2.2
admissions. When admissions related to PC were
excluded, the average number of admissions fell to 0.44.
The relative morbidity was 6.75 (6.39–7.13) and 1.35
(1.26–1.44) after exclusion of PC-related admissions. In
the following 9 y patients were still admitted significantly
more often than controls RR 2.69 (2.61–2.77). However,
when PC-related admissions were excluded, the RR was
close to unity 0.86 (0.83–0.89; Figure 1).
Overall, the 4774 patients were hospitalized 251,695
days within the first 10 y following diagnosis compared
with 74,563 days in age-matched controls. In the year of
diagnosis patients were hospitalized 100,269 days com-
pared to 15,658 days among controls. The total number of
days and the number of days spent in hospital after
exclusion of discharges with PC as one of the discharge
diagnosis is shown in Figure 2. The following 9 y patients
spent 151,426 days in hospital compared with 58,905 days
among controls (Table 1).
Admissions with PC as discharge diagnosis accounted
for 76% of the days spent in hospital. When admissions
Figure 1 Relative morbidity ((no. admissions=patient=y)=(no. admis-
sions=control=y)) in patients with clinically localized PC (95% CI). All
discharges, and PC discharges excluded.
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with PC as discharge diagnosis were excluded patients
were hospitalized 17,050 days in the year of diagnosis and
43,481 in the following 9 y.
In the year of diagnosis patients were on average
hospitalized for 22.3 days compared with 3.5 days
among controls. In the following 9 y a significant decline
in excess morbidity was found (Figure 3). From the
second to the tenth year following diagnosis patients on
average were hospitalized 6.1 days more than controls.
Table 1 shows the estimated costs associated with
hospitalizations of patients and controls. The overall
cost from the year of diagnosis and the following 9 y
was approximately, US$125.8 million in the patients
compared with US$37.3 million in the controls. This
difference in need for hospital care amounted to an
approximate extra cost per patient of US$18,500.
Discussion
Until 1994, expectant management of localized PC has
been the routine strategy in Denmark and no early
detection policy has been implemented.10 Deferred endo-
crine therapy, regardless of age and stage, has been
routine treatment for PC in Denmark, and only a few
patients have been treated with curative intent.11
In this study, we described morbidity based on infor-
mation from the DHDR. This registry has previously been
found suitable for epidemiological studies12 and good
correlation between hospital records and information
recorded in the registry has been demonstrated.13
The morbidity in patients with PC was compared to a
randomly selected age-matched background population
assuming that possible differences between patients and
controls were due to PC.
Theoretically, the results may be biased by the selection
procedure. The controls were only accepted if they had no
previous or subsequent clinical diagnosis of PC. If histolo-
gical sub-clinical PC increases the morbidity, the selection
of controls may have lead to an underestimation of the
morbidity in that group. Still, since PC is a frequent
finding at autopsy,14; 15 histological PC must be frequent
among controls. This could result in an underestimation
of the impact of PC, and a larger difference in morbidity
might have been found if controls without even histolo-
gical PC could have been identified. These considerations,
however, are purely academic, and our study demon-
strates the difference between clinical PC and no clinical
PC.
We found that the morbidity was significantly higher
among patients with clinically localized PC than among
age-matched controls. The difference in admission-rate
was highest in the year of diagnosis. Since the majority of
PC cases in Denmark during the study period were
diagnosed during hospitalization, the morbidity in the
year of diagnosis may overestimate the morbidity asso-
ciated with PC. However, in the 9 y following the year of
diagnosis, admission rates showed only minor variations
and patients were on average admitted 2.7 times more
often than controls. When admissions related to PC were
excluded, the relative morbidity was 0.86, thus close to
unity. This finding indicates that if morbidity associated
with PC is eliminated, the PC patients would exhibit
Table 1 Length of and costs associated with hospitalization of patients with clinically localized PC compared with controls
Year
Years
at risk
Patients (n 4774)
all discharges
Patients (n 4774)
prostate cancer
discharges excluded
Controls
(n 4774)
1 4488 100,269 days US$50.1 million 17,050 days US$8.5 million 15,658 days US$7.8 million
2–10 15,100 151,426 days US$75.7 million 43,481 US$21.7 million 58,905 days US$29.5 million
Total 19,598 251,695 days US$125.8 million 60,981 US$30.2 million 74,563 US$37.3 million
Figure 2 The number of days per year hospitalized for PC patients, all
discharges and PC discharges excluded, respectively. The number of days
per year hospitalized for controls.
Figure 3 Excess morbidity (no. days=patient=y)7 (no. days=control=y)
in patients with clinically localized PC.
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morbidity comparable to the background population. The
fact that the relative morbidity was significantly below 1
may be explained by misclassification of PC as discharge
diagnosis in cases where PC was not the direct cause of
admission.
Excess morbidity declined during the period of follow-
up. There are several explanations to this finding. Patients
with the most aggressive PC have been shown to have the
highest need for hospitalization.3 These patients also have
the worst prognosis and will be lost from follow-up first.
Also, with extended follow-up, increasing competing
morbidity will tend to reduce the relative impact of PC
morbidity on the total morbidity.
The cost of hospitalization in Denmark varies from
US$350 to 625, with an average of around US$500 per
day.8 Overall, the patients were hospitalized a total of
177,132 days more than controls, or approximately 37
days per patient. This difference was equivalent to a cost
of approximately US$88.5 million, and represents a
potential gain if a curative therapy without complications
existed. This gain is, however, overestimated as both
treatment, treatment failures and complications following
curatively intended therapy will add to the costs of a
curative treatment strategy.16; 17
The patients in our material represent a subgroup of
patients believed to have had a clinically localized PC;
further, their life expectancy would have made them
candidates for curatively intended therapy.18,19 When
managed expectantly, this group of patients was found
to have a significant excess morbidity leading to signifi-
cant costs compared to the background population. Our
findings demonstrate that these patients endure consider-
able morbidity related to PC and a significant impact on
quality of life must be assumed. However, not all patients
included in the study had truly localized, ie organ-
confined PC, since the retroactive selection makes a
significant under-staging likely. Thus, they would not
all have been candidates for curative therapy. Nonethe-
less, it seems justified to question whether curative ther-
apy in this group of patients would have reduced
morbidity and cost.
In future studies of early prostate cancer, not only
mortality and quality of life, but also morbidity and
costs have to be considered when evaluating the outcome
of various treatment strategies.
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